Search PubMed⌕ Search

Biomedical subjects

S S Iakushin

Publications and source records attributed to S S Iakushin.

18 recordsLinked to original sources
PubMed2003

[Long-term effects of structum administration (according to data from multicenter trial)].

AIM: To evaluate duration of a clinical response to the drug structum in patients with osteoarthrosis (OA) of the knee and hip joints as well as structum effects on OA course and that of concomitant diseases. MATERIAL AND METHODS: The duration of a clinical response to structum after the end of the treatment and its effect on OA and concominant diseases course were studied for 12 months in 9 centers participating in the study of the drug efficacy and tolerance in patients with gon- and coxarthrosis in an open multicenter randomized controlled 6-month trial. Out of 555 patients with OA of the knee and hip joints enrolled in the first study, the examination covered 373 patients: 159 patients of the test group treated for 6 months with structum and 214 controls. By basic clinical parameters the groups were similar. Clinical examination was made after structum treatment and 12 months later and included assessment of the number of exacerbations, hospitalizations, outpatient consultations, days of temporary disability for OA, pain in the joints while walking and at rest by the visual scale, Leken's functional index, x-ray pictures of the joints, administration of nonsteroidal anti-inflammatory drugs (NSAID), exacerbations of concomitant diseases (gastrointestinal diseases, arterial hypertension, ischemic heart disease). RESULTS: An overall functional Leken's index in patients with gon- and coxarthrosis given structum 12 months after the treatment did not reach the initial values as well as pain and daily need in NSAID. Structum effect in patients with knee joint OA persisted for 4.6 months, in hip joint OA--4.1 months; in patients with stage I-II the effect lasted longer than in stage III (5.2 and 4.6 months vs 4.17 and 3.24 months, respectively. Even short-term therapy with structum reduced the number of further exacerbations, hospitalizations and visits to their doctor. 12 months after structum therapy the effect persisted in 40% patients. Frequency of exacerbations of the concomitant diseases was less than in patients on continuous NSAID. CONCLUSION: Structum is a highly effective drug against OA as it acts long, reduces frequency of exacerbations, hospitalizations, visits to the doctor, duration of disability, NSAID requirement and improves the course of some concomitant diseases.

Chondroitin Sulfates↗
PubMed2002

[Assessment of safety and antihypertensive efficacy of a cardioselective beta-blocker nebivolol in patients with hypertension and concomitant chronic obstructive bronchitis].

Safety, tolerability and antihypertensive efficacy of a cardioselective beta-blocker nebivolol was studied in 30 patients with mild and moderate hypertension and concomitant stage I chronic obstructive bronchitis. Nebivolol (5 mg/day) was given for 1 month; in 5 patients complementary hydrochlorothiazide (12.5 mg/day) was required for sufficient antihypertensive effect. Nebivolol was well tolerated (only 1 patient complained of head ache), did not cause worsening of bronchitis and spirometric parameters, exerted no cardiodepressive action, and did not induce apparent disturbances of metabolism.

Adrenergic beta-Antagonists↗
PubMed2001

[Results of the multicenter clinical trial of structum preparation in Russia].

AIM: To study clinical effectiveness and tolerance of structum in patients with osteoarthrosis (OA) of the knee joints (KJ) and hip joints (HJ) in a multicenter open randomised trial. MATERIAL AND METHODS: A 6-month trial of effectiveness and tolerance of structum has been performed in 9 medical centers and included outpatients (males and females) with KJ OA or HJ OA satisfying the OA diagnostic criteria of the American Rheumatology College, having x-ray stage I-III according to Kellgren-Lawrence with manifest pain, a total functional Leken index from 4 to 11, regular intake of non-steroid antiinflammatory drugs (NAID) for 30 days in the last 3 months. Consent was obtained from each patient. 192 patients received structum, 363 matched patients served control. Structum was given per os for 3 weeks in a dose of 1.5 g/day then in a dose 1.0 g/day up to 6 months. The patients continued on NAID. The patients' examination was performed in the beginning of the study, at its months 3 and 6. RESULTS: Leken index in HJ and KJ OA significantly fell after 3 months of structum treatment. Up to month 6 it fell still further (p < 0.05). After 6 months of treatment pain syndrome relieved both at rest and movement, pain at rest disappeared fully in 57% of NJ OA patients and 46% of HJ OA patients, for movement pain it was 17 and 13%, respectively. During the treatment NAID intake was less required in both groups (p < 0.05) while 55% of patients in both groups could discontinue NAID after 6 months of the treatment. Tolerance of the drug was rather good, side effects were mild. CONCLUSION: Structum (chondroitin sulphate) is an effective drug for treatment of KJ and HJ OA: it relieves pain, preserves and improves articular function, allows to reduce or discontinue NAID, is well tolerated.

Anti-Inflammatory Agents, Non-Steroidal↗
PubMed2000

[Arthrotec treatment of rheumatoid arthritis].

AIM: To try arthrotek, a combined drug, in patients with rheumatoid arthritis (RA). MATERIALS AND METHODS: 10 RA women aged 30 to 60 years with endoscopically verified minimal affection of gastroduodenal mucosa (not more than 25 hemorrhages and/or 5 erosions) received arthrotek (1 tablet 3 times a day for 3 months). The efficacy was judged by changes in the joints and gastroduodenal lesions. RESULTS: The 3-month treatment produced positive changes in the main auricular and gastroduodenal symptoms. Side effects (head ache, diarrhea, sleepiness) disappeared after reducing the day dose to 2 tablets. CONCLUSION: Arthrotek proved highly effective against RA. It is also a good gastroprotector promoting healing of gastroduodenal erosions.

Administration, Oral↗
PubMed1992

[Experience in the combined treatment of different clinical forms of chronic bronchitis with new phytotherapeutic mixtures].

As many as 68 patients suffering from chronic bronchitis (CB) were subjected to combined treatment by new mixtures of medicinal herbs given per os and by inhalation. Administration of the first (antiseptic) or the second (broncholytic) mixture was determined by the clinical variant of CB. In 81% of cases, the method produced a beneficial effect, contributing to the shortening of the times of the patients' treatment in the hospital. The long-term results were also positive, allowing the simultaneous use of the phytotherapeutic mixtures per os and by inhalation in the treatment of CB patients.

Administration, Inhalation↗
PubMed1990

[Use of phthivazide in the treatment of patients with acute pneumonia and chronic bronchitis].

The treatment scheme of 540 patients with acute pneumonia and chronic bronchitis involved a 0.5 g ftivazid three times a day for 15-20 days. Compared with control groups of patients on the standard therapy, the drug presents a more advantageous treatment. Adequate efficacy and tolerance of the drug ftivazid make it appropriate for use in acute pneumonia and chronic bronchitis.

Acute Disease↗
PubMed1990

[Use of new mixtures of medicinal plants in the treatment of chronic bronchitis].

Three new prescriptions of drug plants were included into combined hospital treatment of 156 patients with chronic bronchitis. Each of the three mixtures was to treat a certain clinical form of chronic bronchitis being composed of plants with specific mechanism of action. The mixture was taken a tablespoonful 8-10 times a day. Pronounced and moderate effect of the therapy was achieved in 95.6% of those treated. This justifies the use of the mixtures as an adjuvant therapy in basic treatment of chronic bronchitis.

Anti-Inflammatory Agents↗
PubMed1989

[Lysosomal cation proteins of neutrophils in acute pneumonia and chronic bronchitis].

A decrease in the content of lysosomal cation proteins in 75 patients with acute pneumonia and chronic bronchitis and the recovery of their level in pneumonia patients after treatment allows the assessment of non-specific reactivity of the organism. The reliable difference in the level of cation proteins in ordinary and purulent chronic bronchitis enables one to use this test for the differentiation of the character of inflammation.

Acute Disease↗